Open AccessA Post Hoc Holter ECG Analysis of Olodaterol and Formoterol in Moderate-to-Very-Severe COPD
Author(s) -
Stefan Andreas,
Ulrich Bothner,
Alberto de la Hoz,
Isabel Kloer,
Matthias Trampisch,
Peter Alter
Publication year - 2020
Publication title -
international journal of chronic obstructive pulmonary disease/international journal of copd
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 67
eISSN - 1178-2005
pISSN - 1176-9106
DOI - 10.2147/copd.s246353
Subject(s) - formoterol , medicine , copd , placebo , heart rate , cardiology , anesthesia , post hoc analysis , electrocardiography , heart disease , asthma , blood pressure , budesonide , alternative medicine , pathology
Patients with chronic obstructive pulmonary disease (COPD) are at risk of developing cardiac arrhythmias and elevated heart rate. A theoretical mechanistic association based on the interaction of long-acting β 2 -agonists (LABAs) with adrenoreceptors in the heart and vasculature is assumed as a potential class-related risk. Therefore, we performed a pooled analysis of Holter electrocardiogram (ECG) data from four 48-week, randomized, double-blind, placebo-controlled, parallel-group, Phase III clinical trials evaluating olodaterol (5 μg or 10 μg) or formoterol (12 µg) versus placebo.